TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14987306
Drug: Cetirizine (CTZ)
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine (CTZ) 10 mg plus montelukast (MSK) 10 mg
Study: 14987306
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (FPANS, FPANS plus CTZ, FPANS plus MSK, CTZ plus MSK)
Study: 15101888
Drug: Fentanyl 25-microg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25-microg/h patch with local heat
Study: 15101888
Drug: Fentanyl 25-microg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25-microg/h patch without local heat
Study: 30888908
Drug: Combined locoregional
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined locoregional and systemic therapy
Study: 30888908
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy alone
Study: 29877727
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for pediatric anxiety disorders
Study: 26530743
Drug: 48 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 Gy in 4 consecutive daily fractions (arm 2)
Study: 21961181
Drug: Thalidomide induction
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide induction therapy
Study: 14558437
Drug: Theophyllin 400
Normalized name: theophylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophyllin 400 retard Heumann (formulation A) - 400 mg once daily
Study: 14558437
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (formulation B) - 133 mg t.i.d.
Study: 14558437
Drug: Theophylline sustained
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline sustained release formulation C - 375 mg once daily
Study: 9487832
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Interclean‐ID2 with Flexi‐Tip gingival massage attachment
Study: 31902935
Drug: Educational Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational Program for Promoting Appropriate Self-medication via Pharmacies and Pharmacists
Study: 31902935
Drug: Medication/health class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication/health class (control group)
Study: 15908647
Drug: Doxorubicin-cyclophosphamide (AC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-cyclophosphamide (AC) neoadjuvant chemotherapy (n = 24)
Study: 15908647
Drug: Doxorubicin-docetaxel (AD)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin-docetaxel (AD) neoadjuvant chemotherapy (n = 24)
Study: 15908647
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of pretreatment biopsy and tumor excised after chemotherapy
Study: 12935395
Drug: Leflunomide at
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide at 20 mg once daily
Study: 12935395
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at 15 mg once weekly
Study: 11214769
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg/day for 2 days and then 25 mg/day for 5 days
Study: 2680994
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg mesterolone daily
Study: 2680994
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg mesterolone daily
Study: 781228
Drug: Fenoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen (200 to 800 mg every six hours, median daily dose 1.8 gm)
Study: 28010884
Drug: Lumbar cistern
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar cistern drainage combined with intrathecal injection of antibiotics (LCD-ITI)
Study: 23665469
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 150mg daily
Study: 23665469
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 75mg daily
Study: 19057373
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 5 mg/kg/d
Study: 19057373
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 20 mg/kg/d
Study: 27596682
Drug: Submerged implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged implants (n=30)
Study: 25877514
Drug: Social‐cognitive theory‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social‐cognitive theory‐guided oral hygiene intervention (three face‐to‐face educational hands‐on sessions facilitated by a dentist)
Study: 16164475
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment and handholding (Control)
Study: 12098616
Drug: Ketamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.1 mg/kg followed by 4 microg/kg/min)
Study: 12004808
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine and ketamine
Study: 10398973
Drug: LumenHance (manganese
Approvals — FDA: no, EMA: no, PMDA: no
Description: LumenHance (manganese chloride-based oral contrast agent)
Study: 1702939
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition administered by needle‐catheter jejunostomy
Study: 1702939
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition administered by total parenteral nutrition
Study: 23740226
Drug: Subcutaneous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous golimumab 50 mg monthly for 6 months
Study: 23740226
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus subcutaneous golimumab
Study: 22852834
Drug: Nurse-administered Tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered Tobacco Tactics intervention
Study: 20823391
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention including pill counting, family support, and educational information.
Study: 18634504
Drug: YU BHK
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YU BHK Rabivak vaccine candidate
Study: 18634504
Drug: Rabipur (commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabipur (commercially available vaccine)
Study: 15805799
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (specifics not provided)
Study: 15805799
Drug: Other combinations
Normalized name: Iron in other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other combinations of antioxidant therapies
Study: 12394560
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for cancer treatment-related fatigue
Study: 25509922
Drug: Gepatomax Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepatomax Forte in conjunction with basal therapy for 4 weeks
Study: 25509922
Drug: Basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal therapy only for 4 weeks
Study: 20667604
Drug: Carboplatin chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin chemotherapy (3-4 courses)
Study: 20667604
Drug: Carboplatin chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin chemotherapy (higher doses)
Study: 20667604
Drug: Baseline measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline measurement (before chemotherapy)
Study: 11260540
Drug: Cyclosporine (Neoral)
Normalized name: CYCLOSPORINE (NEORAL) 25MG CAP
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (Neoral) treatment until clearance or for a maximum of 12 weeks, followed by randomization into two groups: Group A (stop abruptly) and Group B (taper dose by 1 mg/kg per day until cessation within 4 weeks)
Study: 11260540
Drug: Cyclosporine (Neoral)
Normalized name: CYCLOSPORINE (NEORAL) 25MG CAP
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (Neoral) treatment
Study: 9652881
Drug: Low-dose nitroglycerin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nitroglycerin patches (5 mg/24 h each)
Study: 8093138
Drug: Cranberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry beverage (300 mL per day)
Study: 3147901
Drug: Oxyntomodulin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxyntomodulin infusion
Study: 24132705
Drug: Compound Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Amlodipine Tablets with high-fat breakfast
Study: 24132705
Drug: Compound Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Amlodipine Tablets with overnight fast
Study: 23531328
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (900 mg DHA plus 180 mg EPA)
Study: 20193646
Drug: Continuation electroconvulsive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation electroconvulsive therapy (C-ECT) with 10 treatments
Study: 19013293
Drug: Triiodothyronine (T(3))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine (T(3)) at doses of 50 to 75 microg/d
Study: 8921055
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified human follicle‐stimulating hormone (FSH‐HP), administered s.c. (n = 19)
Study: 8921055
Drug: Human menopausal
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotrophin (HMG), administered i.m. (n = 20)
Study: 8255126
Drug: Dipyrone 1
Normalized name: dipyrone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1 g
Study: 30913305
Drug: Standard fractionation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fractionation radiotherapy concurrent with cisplatin (RTOG-0129)
Study: 30913305
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation radiotherapy concurrent with cisplatin (RTOG-0522)
Study: 30217172
Drug: IFN β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN β‐1a 22 μg
Study: 30217172
Drug: IFN β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN β‐1a 44 μg
Study: 20656351
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections for CNV
Study: 15231557
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (10 mg) plus promethazine (25-50 mg mix)
Study: 11438315
Drug: CEE 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.45 mg/day
Study: 11438315
Drug: CEE 0.625/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625/MPA 2.5 mg/day
Study: 11438315
Drug: CEE 0.45/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.45/MPA 2.5 mg/day
Study: 11438315
Drug: CEE 0.45/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.45/MPA 1.5 mg/day
Study: 11438315
Drug: CEE 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3 mg/day
Study: 11438315
Drug: CEE 0.3/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3/MPA 1.5 mg/day
Study: 27833860
Drug: Lignocaine (2%)
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine (2%) injection with topical adrenaline (1:10,000)
Study: 15610370
Drug: Ketotifen fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate 0.025% ophthalmic solution (single dose)
Study: 15610370
Drug: Ketotifen fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate 0.025% ophthalmic solution (multiple doses)
Study: 15610370
Drug: Ketotifen fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate 0.025% ophthalmic solution (single and multiple doses)
Study: 15610370
Drug: Vehicle placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo (single dose)
Study: 15610370
Drug: Vehicle placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo (multiple doses)
Study: 11581550
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/d for first 5 days, then 5 g/d)
Study: 4393372
Drug: Methysergide 3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide 3-6 mg daily
Study: 31945659
Drug: Infiltration anaesthesia
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration anaesthesia (IA) with 0.2% ropivacaine (RPV) and FNT 50 μg
Study: 31945659
Drug: Infiltration anaesthesia
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration anaesthesia (IA) with 0.2% bupivacaine (BPV) and FNT 50 μg
Study: 25711974
Drug: Automated, telephone‐based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated, telephone‐based, interactive voice response (IVR) intervention, called twice weekly
Study: 21485398
Drug: non-immersion control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-immersion control with no drug
Study: 19751000
Drug: All-polyethylene step-cut
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-polyethylene step-cut implants
Study: 19751000
Drug: Metal-backed nonmodular
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal-backed nonmodular fixed-bearing implants
Study: 19751000
Drug: Modular fixed-bearing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modular fixed-bearing implants
Study: 16981140
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol plus MPA
Study: 15287931
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily plus a mildly reduced-calorie diet
Study: 21248612
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid modified‐immediate‐release (MIR) 1.3 g (2 650‐mg tablets)
Study: 21248612
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid delayed‐release (DR) 1.3 g (2 650‐mg tablets)
Study: 21248612
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid MIR 1.3 g dosed every 8 hours for 5 days
Study: 21248612
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid DR 1.3 g
Study: 20337841
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (Induction Chemotherapy and Chemoradiation)
Study: 15188756
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg/kg)
Study: 22316839
Drug: School based
Approvals — FDA: no, EMA: no, PMDA: no
Description: School based exercise program (twice a week for six weeks, 50 minutes per session)
Study: 11277962
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg once daily for 6 weeks
Study: 9252849
Drug: 1,25-dihydroxyvitamin D
Normalized name: 1,25-dihydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D (0.5 microgram twice a day for 5 days) + calcium carbonate (1,500 mg/day) + carbocalcitonin (40 UMRC intramuscularly three times weekly)
Study: 8503418
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (Epo)
Study: 8503418
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human erythropoietin (Epo)
Study: 28490515
Drug: Iron (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (60 mg)
Study: 17509587
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) therapy (100 microg/d)
Study: 16865142
Drug: 20% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% citric acid solution and photo‐activated disinfection
Study: 16865142
Drug: 20% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% citric acid and 2.25% sodium hypochlorite solutions
Study: 12789897
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment Program
Study: 7934682
Drug: Atropine 8
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine 8 micrograms/kg and edrophonium 0.75 mg/kg
Study: 29216361
Drug: OBE2109 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE2109 100 mg
Study: 29216361
Drug: OBE2109 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE2109 200 mg
Study: 29216361
Drug: OBE2109 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE2109 100 mg/1.0 mg/0.5 mg (add-back therapy)
Study: 29216361
Drug: OBE2109 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE2109 200 mg (with E2/NETA)
Study: 18301060
Drug: Viral suppression
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral suppression (by > 1.0 log10 copies/ml or to < 400 copies/ml)
Study: 12185552
Drug: Sumatriptan 3
Normalized name: SUMATRIPTAN 3MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 3 mg
Study: 7133973
Drug: pirprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirprofen (600 mg/day)
Study: 29017796
Drug: Collagen tripeptide
Normalized name: tripeptide-29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen tripeptide (CTP) 3.9g daily for 12 weeks
Study: 17341247
Drug: 0.25 mg/d
Normalized name: fluoride 0.25 mg/drop oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/d of micronized 17beta-estradiol (estrogen therapy, n=32)
Study: 11153533
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg daily for 2 weeks)
Study: 3342289
Drug: New tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet formulation of carbocysteine
Study: 3342289
Drug: Syrup containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup containing carbocysteine
Study: 3342289
Drug: Capsules containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing carbocysteine
Study: 30048223
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL irrigation volume
Study: 30048223
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL irrigation volume
Study: 30048223
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 50 mL and 200 mL irrigation volumes
Study: 21683750
Drug: EmulGold(®) (EG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EmulGold(®) (EG) at doses of 40 g
Study: 21683750
Drug: PreVitae(®) (PV)
Normalized name: Brevital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PreVitae(®) (PV) at doses of 40 g
Study: 21683750
Drug: EmulGold(®) (EG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EmulGold(®) (EG) at doses of 10 or 20 g
Study: 21683750
Drug: EmulGold(®) (EG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EmulGold(®) (EG) at doses of 5 and 10 g
Study: 21683750
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of both gums compared to negative control
Study: 21683750
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (250 ml of water)
Study: 16550734
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 7 days
Study: 16550734
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 7 days
Study: 16550734
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily with clarithromycin 500 mg b.i.d. for 1 week
Study: 11145281
Drug: PPI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI treatment (30 mg lansoprazole/day for 8 weeks followed by 15 or 30 mg lansoprazole or 20 mg omeprazole/day for 12 months)
Study: 2000109
Drug: Surfactant as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant as prophylaxis (90 mg intratracheal dose at delivery)
Study: 2000109
Drug: Surfactant as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant as rescue therapy (90 mg intratracheal dose several hours after delivery if criteria met)
Study: 2000109
Drug: Surfactant as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant as rescue therapy (for infants ≤ 26 weeks' gestation)